WO2013017545A1 - Souris transgéniques humanisées hla-a2 / hla-dp4 et leurs utilisations en tant que modèle expérimental pour la recherche biomédicale et le développement biomédical - Google Patents

Souris transgéniques humanisées hla-a2 / hla-dp4 et leurs utilisations en tant que modèle expérimental pour la recherche biomédicale et le développement biomédical Download PDF

Info

Publication number
WO2013017545A1
WO2013017545A1 PCT/EP2012/064813 EP2012064813W WO2013017545A1 WO 2013017545 A1 WO2013017545 A1 WO 2013017545A1 EP 2012064813 W EP2012064813 W EP 2012064813W WO 2013017545 A1 WO2013017545 A1 WO 2013017545A1
Authority
WO
WIPO (PCT)
Prior art keywords
hla
mouse
response
antigen
antigens
Prior art date
Application number
PCT/EP2012/064813
Other languages
English (en)
Inventor
Yu Chun LONE
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of WO2013017545A1 publication Critical patent/WO2013017545A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La présente invention concerne des souris transgéniques comprenant des gènes non fonctionnels H2 de classe I et H2 de classe II et comprenant un transgène fonctionnel HLA-A2 et un transgène fonctionnel HLA-DP4. La présente invention concerne également des procédés d'identification de la présence d'un ou plusieurs épitopes dans un antigène candidat ou d'un groupe d'antigènes, des procédés de détermination de la réponse immunitaire d'une souris à la suite de son immunisation par un antigène ou un vaccin ou à la suite de son traitement par un composé immunothérapeutique, des procédés de comparaison de l'efficacité d'une réponse induite par au moins deux compositions de vaccin ou immunothérapeutiques, et des procédés de détermination de savoir si une composition de vaccin ou immunothérapeutique pose un risque d'induction d'une maladie auto-immune lorsqu'elle est administrée à un être humain. L'invention concerne en outre de cellules murines transgéniques comprenant des gènes non fonctionnels H2 de classe I et H2 de classe II et comprenant un transgène fonctionnel HLA-A2 et un transgène fonctionnel HLA-DP4, et des trousses pour l'identification de la présence d'un ou plusieurs épitopes dans un antigène candidat ou un groupe d'antigènes.
PCT/EP2012/064813 2011-07-29 2012-07-27 Souris transgéniques humanisées hla-a2 / hla-dp4 et leurs utilisations en tant que modèle expérimental pour la recherche biomédicale et le développement biomédical WO2013017545A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305998.4 2011-07-29
EP11305998 2011-07-29

Publications (1)

Publication Number Publication Date
WO2013017545A1 true WO2013017545A1 (fr) 2013-02-07

Family

ID=46640004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/064813 WO2013017545A1 (fr) 2011-07-29 2012-07-27 Souris transgéniques humanisées hla-a2 / hla-dp4 et leurs utilisations en tant que modèle expérimental pour la recherche biomédicale et le développement biomédical

Country Status (1)

Country Link
WO (1) WO2013017545A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020053304A2 (fr) 2018-09-14 2020-03-19 Scancell Limited Épitopes
CN112575037A (zh) * 2019-09-29 2021-03-30 上海市公共卫生临床中心 一种嵌合人hla-dp基因组区域的人源化转基因小鼠模型的构建方法
WO2021214022A1 (fr) 2020-04-21 2021-10-28 Scancell Limited Peptides de nucléophosmine citrulinés utilisés en tant que vaccins anticancéreux
DE102020120377A1 (de) 2020-08-03 2022-02-03 Hamm Ag Ummantelung für eine Bodenbearbeitungswalze
WO2022106696A2 (fr) 2020-11-23 2022-05-27 Scancell Limited Réponses antitumorales à des cytokératines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
WO2006092515A1 (fr) 2005-03-04 2006-09-08 Centre National De La Recherche Scientifique (C.N.R.S.) Souris transgeniques et leurs applications comme modele experimental
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2006092515A1 (fr) 2005-03-04 2006-09-08 Centre National De La Recherche Scientifique (C.N.R.S.) Souris transgeniques et leurs applications comme modele experimental
US20100138936A1 (en) * 2005-03-04 2010-06-03 Yu-Chun Lone Transgenic Mice and Use Thereof as an Experimental Model

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, MACK PUB.
CASTELLI F A ET AL: "HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 169, no. 12, 15 December 2002 (2002-12-15), pages 6928 - 6934, XP002238415, ISSN: 0022-1767 *
E. J. ROBERTSON: "In: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach", 1987, IRL PRESS
PAJOT A ET AL: "A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 34, no. 11, 1 November 2004 (2004-11-01), pages 3060 - 3069, XP002314836, ISSN: 0014-2980, DOI: 10.1002/EJI.200425463 *
PAJOT A. ET AL., EUR J IMMUNOL, vol. 34, 2004, pages 3060 - 3069
PAJOT ET AL., EUR. J. IMMUNOL., vol. 34, 2004, pages 3060 - 3069
PASCOLO S. ET AL., J EXP MED, vol. 185, 1997, pages 2043 - 2051
PASCOLO STEVE ET AL: "HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from beta-2 microglobulin (beta-2m) HLA-A2.1 monochain transgenic H-2D-b beta-2m double knockout mice", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 185, no. 12, 1 January 1997 (1997-01-01), pages 2043 - 2051, XP002469861, ISSN: 0022-1007, DOI: 10.1084/JEM.185.12.2043 *
RU ZHITAO ET AL: "Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein", PLOS ONE, vol. 7, no. 3, March 2012 (2012-03-01), XP002685313 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020053304A2 (fr) 2018-09-14 2020-03-19 Scancell Limited Épitopes
CN112575037A (zh) * 2019-09-29 2021-03-30 上海市公共卫生临床中心 一种嵌合人hla-dp基因组区域的人源化转基因小鼠模型的构建方法
WO2021214022A1 (fr) 2020-04-21 2021-10-28 Scancell Limited Peptides de nucléophosmine citrulinés utilisés en tant que vaccins anticancéreux
DE102020120377A1 (de) 2020-08-03 2022-02-03 Hamm Ag Ummantelung für eine Bodenbearbeitungswalze
EP3951065A1 (fr) 2020-08-03 2022-02-09 Hamm AG Gaine pour un rouleau de traitement du sol
WO2022106696A2 (fr) 2020-11-23 2022-05-27 Scancell Limited Réponses antitumorales à des cytokératines

Similar Documents

Publication Publication Date Title
JP7285279B2 (ja) 新生物ワクチン用製剤
CN110809716B (zh) 基于hla的方法和组合物及其用途
TWI750122B (zh) 用於贅瘤疫苗之調配物及其製備方法
US8282935B2 (en) Materials and methods relating to improved vaccination strategies
CN109748953B (zh) 用于治疗多种肿瘤(例如包括nsclc在内的肺癌)的新型免疫疗法
WO2013017545A1 (fr) Souris transgéniques humanisées hla-a2 / hla-dp4 et leurs utilisations en tant que modèle expérimental pour la recherche biomédicale et le développement biomédical
Ru et al. Development of a humanized HLA-A2. 1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein
EP3322718B1 (fr) Vaccins anticancéreux histones
ZA200605304B (en) Targeted immunogens
Dikopoulos et al. Novel peptide‐based vaccines efficiently prime murine “help”‐independent CD8+ T cell responses in the liver
JP5478003B2 (ja) ヒトの主要組織適合複合体（ｍｈｃ）の表現型を有するトランスジェニックマウス、その実験のための使用および応用方法
Petersen Interrogating T cells specific to mutated and shared tumor epitopes in mouse and man
JP2007502602A (ja) 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター
Kalfayan Mucosal immunizations in a humanized transgenic mouse model and development of novel multimeric tools for detection of cellular immunity towards an HIV vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12745443

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12745443

Country of ref document: EP

Kind code of ref document: A1